Chemed Stock Forecast, Price & News

Chemed's stock was trading at $414.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CHE stock has increased by 15.5% and is now trading at $478.32.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Chemed.

Chemed is scheduled to release its next quarterly earnings announcement on Tuesday, February 16th 2021.
View our earnings forecast for Chemed.

Chemed Co. (NYSE:CHE) announced its quarterly earnings results on Thursday, October, 29th. The company reported $4.86 EPS for the quarter, topping analysts' consensus estimates of $3.97 by $0.89. The business earned $528.30 million during the quarter, compared to the consensus estimate of $514.22 million. Chemed had a net margin of 12.99% and a return on equity of 36.71%. The company's quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the previous year, the company earned $3.46 earnings per share.
View Chemed's earnings history.

Chemed declared a quarterly dividend on Thursday, August 6th. Stockholders of record on Monday, August 17th will be paid a dividend of $0.34 per share on Friday, September 4th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date is Friday, August 14th. This is an increase from Chemed's previous quarterly dividend of $0.32.
View Chemed's dividend history.

Chemed updated its FY20 earnings guidance on Thursday, October, 29th. The company provided EPS guidance of $18.00-18.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.35.

3 equities research analysts have issued 1 year price targets for Chemed's stock. Their forecasts range from $490.00 to $535.00. On average, they expect Chemed's stock price to reach $520.00 in the next year. This suggests a possible upside of 8.7% from the stock's current price.
View analysts' price targets for Chemed.

Chemed saw a increase in short interest during the month of October. As of October 15th, there was short interest totaling 168,500 shares, an increase of 22.5% from the September 30th total of 137,600 shares. Based on an average trading volume of 64,900 shares, the short-interest ratio is currently 2.6 days. Currently, 1.1% of the shares of the company are sold short.
View Chemed's Short Interest.

Some companies that are related to Chemed include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), R1 RCM (RCM), The Providence Service (PRSC), CorVel (CRVL), MEDNAX (MD), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Biosciences (IDXG).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), Home Depot (HD), Johnson & Johnson (JNJ), AbbVie (ABBV), Abbott Laboratories (ABT), CVS Health (CVS), The Boeing (BA), UnitedHealth Group (UNH), Verizon Communications (VZ) and Chevron (CVX).

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Chemed's stock is owned by a variety of retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (2.19%), Standard Life Aberdeen plc (0.68%), Assenagon Asset Management S.A. (0.63%), Copeland Capital Management LLC (0.53%), Trinity Street Asset Management LLP (0.38%) and Envestnet Asset Management Inc. (0.36%). Company insiders that own Chemed stock include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee, Thomas P Rice and Walter L Krebs.
View institutional ownership trends for Chemed.

CHE stock was sold by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp, Copeland Capital Management LLC, BNP Paribas Arbitrage SA, Robeco Institutional Asset Management B.V., Alberta Investment Management Corp, WINTON GROUP Ltd, Dorsey Wright & Associates, and Nisa Investment Advisors LLC. Company insiders that have sold Chemed company stock in the last year include Andrea R Lindell, Donald E Saunders, Frank E Wood, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Patrick P Grace, and Spencer S Lee.
View insider buying and selling activity for Chemed.

CHE stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., North Point Portfolio Managers Corp OH, DekaBank Deutsche Girozentrale, Riverbridge Partners LLC, Envestnet Asset Management Inc., Standard Life Aberdeen plc, Pacer Advisors Inc., and Vestmark Advisory Solutions Inc..
View insider buying and selling activity for Chemed.

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CHE stock can currently be purchased for approximately $478.32.

Chemed has a market capitalization of $7.61 billion and generates $1.94 billion in revenue each year. The company earns $219.92 million in net income (profit) each year or $13.95 on an earnings per share basis. Chemed employs 16,641 workers across the globe.

The official website for Chemed is www.chemed.com.

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at 513-762-6690.